Troikaa mainly focuses on Novel Drug Delivery Systems (NDDS). The company firmly believes in providing superior therapeutic benefits by improvising the formulations through Innovative Technologies.
Six patents have been filed in various areas of drug delivery. To handle competition, Troikaa adopted various multifaceted strategies to help stand their ground in the competitive market. Another fact that helps us stand out is our high quality products.
Troikaa is crowned with the prestigious DSIR (Department of Scientific & Industrial Research) National Award for R&D efforts in Industry (2008) group-1: Physical & Biological Sciences, for developing Dynapar AQ 75mg/1ml - The only 75mg/1ml Diclofenac Injection.
We have signed a MOU with Government of Gujarat during Vibrant Gujarat Global Investor Summit 2009. Troikaa will be establishing a project under biotechnology, anti-cancer / hormones steroids in a land spanning 65 acres at Sanand district, Ahmedabad, Gujarat. The company has chalked out plans to invest Rs.141 crores with the object of expanding its manufacturing capacity as well as to set up state of the art facilities for various Novel Drug Delivery Systems.
Australian patent for Troikaa's Diclofenac injection:
Troikaa Pharmaceuticals, a fast-growing healthcare company, has been granted patent in Australia for its novel drug delivery form of Diclofenac injections - Dynapar AQ, the world's first painless painkiller injection.
The company sought global protection for its novel product by filing a PCT (Patent Cooperation Treaty) application with the World Intellectual Property Organisation. Subsequently, the company filed for global patents in 99 countries, which included regulated as well as non-regulated countries.
Diclofenac injections are used for management of painful inflammatory conditions. Dynapar AQ is a unique high concentration, low viscosity injection of diclofenac sodium delivering the full therapeutic dose of diclofenac in just one millilitre injection volume. It is the only diclofenac injection available in PFS (pre-filled syringe) form.
Speaking about the patent approval, Ketan Patel, Managing Director, Troikaa Pharmaceuticals, said: " The Australia n patent is the first one granted among regulated countries. We are als oexpecting patent approvals in the United States, EU and Canada within the next few weeks. The company has spent about Rs. 3 crores on this endeavour but will reap manifold dividends in return.
The patent desribes the novel clinical advantages of Dynapar AQ over conventional diclofenac injections. Dynapar AQ causes negligible pain and can be injected in the buttocks. This also prevents the embarrassment some patients feel on being injected in the buttocks. More i,portantly Dynapar AQ produces higher blood levels as compared to conventional diclofenac injection, therby providing superior anti-inflammatory action.